7 Hills Pharma, LLC is recruiting patients for a PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma.
The trial, designated NCT06362369, aims to enroll up to 126 participants at 4 sites, including locations in Florida, New Hampshire, Rhode Island.
About the Study
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Treatment Approach
This trial uses a combination of checkpoint inhibitors that was FDA-approved for mesothelioma in 2020.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: 7 Hills Pharma, LLC
- Enrollment target: 126
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- Florida Cancer Specialists, Florida
- Dartmouth Hitchcock, New Hampshire
- Brown University Health Cancer Institute, Rhode Island
- MD Anderson Cancer Center, Texas
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening